Table 1.
Patient demographics and clinical characteristics of the entire study population and further breakdown according to the utilized detection modes.
| Total N (%) | NYONE N (%) | CK20 N (%) | |
|---|---|---|---|
| 49 (100) | 44 (100) | 47 (100) | |
| Gender | |||
| Male | 30 (61.2) | 26 (59.1) | 29 (61.7) |
| Female | 19 (38.8) | 18 (40.9) | 18 (38.8) |
| Age | |||
| Median (range) | 67 (45-89) | 66 (45-89) | 67 (45-89) |
| <65 | 21 (42.9) | 18 (40.9) | 21 (44.7) |
| ≥65 | 28 (57.1) | 26 (59.1) | 26 (55.3) |
| Tumor site | |||
| Colon | 32 (65.3) | 32 (72.7) | 30 (63.8) |
| Right | 16 (50.0) | 16 (50.0) | 15 (50.0) |
| Left | 16 (50.0) | 16 (50.0) | 15 (50.0) |
| Rectum | 17 (34.7) | 12 (27.3) | 17 (36.2) |
| UICC stage | |||
| I | 14 (28.6) | 12 (27.3) | 14 (29.8) |
| II | 9 (18.4) | 9 (20.5) | 8 (17.0) |
| III | 19 (38.8) | 18 (40.9) | 18 (38.3) |
| IV | 7 (14.3) | 5 (11.4) | 7 (14.9) |
| Neoadj. treatment | |||
| Yes | 10 (58.8) | 6 (50.0) | 10 (58.8) |
| No | 7 (41.2) | 6 (50.0) | 7 (41.2) |
| Adjuvant treatment | |||
| Yes | 18 (36.7) | 14 (31.8) | 17 (36.2) |
| No | 31 (63.3) | 30 (68.2) | 30 (63.8) |
The subset of patients who received neoadjuvant treatment solely comprised of patients with rectal carcinoma. UICC, Union internationale contre le cancer.